US Pharma MarketingPanel members said the first-of-a-kind blood test should not be used to replace medical guideline-recommended cancer screenings, however.
Grail multicancer detection test wins FDA advisers’ backing
Grail multicancer detection test wins FDA advisers’ backing is a pharma and life sciences industry update from BioPharma Dive. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Source: BioPharma Dive